Literature DB >> 19724728

A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy.

Robert A Lasser1, Nina R Schooler, Mary Kujawa, John Docherty, Peter Weiden.   

Abstract

Nonadherence to antipsychotic medications in serious, persistent mental illness remains a significant clinical challenge. Long-acting therapy was developed to help improve adherence to schizophrenia therapy and provide an effective means for ameliorating symptoms and preventing relapse. The Agency for Health Care Policy and Research/National Institute of Mental Health Schizophrenia Patient Outcomes Research Team recommends that antipsychotic long-acting therapy be strongly considered for patients who have difficulty adhering to an oral medication regimen or who prefer long-acting therapy. Depot conventional formulations have long been available; for clinicians and patients who would rather use an atypical antipsychotic, studies with risperidone long-acting therapy suggest that it is efficacious and well tolerated. A common concern of clinicians who elect to initiate long-acting therapy is how to introduce the possibility of changing from the current oral antipsychotic to an long-acting therapy injection. As with other aspects of patient care, having an established therapeutic relationship with the patient is advantageous for recommending changes in care, but the way in which the idea is approached may improve the likelihood of its acceptance. To help clinicians broach a recommendation of long-acting therapy with their patients, the GAIN approach was designed as a standard interview process for presenting this option. It encompasses (and is an acronym for) goal setting, action planning, initiating treatment, and nurturing motivation. This novel clinical tool is based on the principles of motivational enhancement therapy, a patient-centered approach that seeks to evoke the patient's own motivation for change, to consolidate the decision to change, and to plan for change. This tool is also based on the Listen-Empathize-Agree-Partner, or LEAP, communication strategy. Motivational enhancement therapy, which is typically brief, has been found effective in several chronic illnesses in both outpatient and inpatient settings. GAIN may be a practical tool for aligning clinician-patient expectations and enhancing long-term maintenance of therapy.

Entities:  

Keywords:  GAIN; LEAP; antipsychotics; interview; long-acting; psychosocial; schizophrenia

Year:  2009        PMID: 19724728      PMCID: PMC2714813     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  24 in total

1.  Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.

Authors:  John M Kane; Mariëlle Eerdekens; Jean-Pierre Lindenmayer; Samuel J Keith; Michael Lesem; Keith Karcher
Journal:  Am J Psychiatry       Date:  2003-06       Impact factor: 18.112

Review 2.  Motivational interviewing: a systematic review and meta-analysis.

Authors:  Sune Rubak; Annelli Sandbaek; Torsten Lauritzen; Bo Christensen
Journal:  Br J Gen Pract       Date:  2005-04       Impact factor: 5.386

3.  Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.

Authors:  Todd P Gilmer; Christian R Dolder; David P Folsom; William Mastin; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2007-07       Impact factor: 3.084

4.  Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome.

Authors:  David M Taylor; Corina Young; Maxine X Patel
Journal:  Int J Neuropsychopharmacol       Date:  2005-11-23       Impact factor: 5.176

5.  Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.

Authors:  E Parellada; R Andrezina; V Milanova; P Glue; M Masiak; M St John Turner; R Medori; W Gaebel
Journal:  J Psychopharmacol       Date:  2005-09       Impact factor: 4.153

6.  Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone.

Authors:  Jean-Pierre Lindenmayer; Kathleen Jarboe; Cynthia A Bossie; Young Zhu; Angelika Mehnert; Robert Lasser
Journal:  Int Clin Psychopharmacol       Date:  2005-07       Impact factor: 1.659

7.  A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

Authors:  George M Simpson; Ramy A Mahmoud; Robert A Lasser; Mary Kujawa; Cynthia A Bossie; Ibrahim Turkoz; Steven Rodriguez; Georges M Gharabawi
Journal:  J Clin Psychiatry       Date:  2006-08       Impact factor: 4.384

8.  Relationships among subjective and objective measures of adherence to oral antipsychotic medications.

Authors:  Dawn I Velligan; Mei Wang; Pamela Diamond; David C Glahn; Desiree Castillo; Scott Bendle; Y W Francis Lam; Larry Ereshefsky; Alexander L Miller
Journal:  Psychiatr Serv       Date:  2007-09       Impact factor: 3.084

9.  Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study.

Authors:  Robin Emsley; Rossella Medori; Liezl Koen; Petrus Paulus Oosthuizen; Dana J H Niehaus; Jonathan Rabinowitz
Journal:  J Clin Psychopharmacol       Date:  2008-04       Impact factor: 3.153

Review 10.  Predictors of noncompliance in patients with schizophrenia.

Authors:  Diana O Perkins
Journal:  J Clin Psychiatry       Date:  2002-12       Impact factor: 4.384

View more
  2 in total

1.  Psychotic disorders in children and adolescents: a primer on contemporary evaluation and management.

Authors:  Jonathan R Stevens; Jefferson B Prince; Laura M Prager; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2014-03-13

Review 2.  Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

Authors:  Georgia L Stevens; Gail Dawson; Jacqueline Zummo
Journal:  Early Interv Psychiatry       Date:  2015-09-25       Impact factor: 2.732

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.